GLP-1 Drugs Are Adding $275 Per Employee to Your Company's Insurance Bill: The Ozempic Cost Crisis Employers Can't Escape

# GLP-1 Drugs Are Adding $275 Per Employee to Your Company's Insurance Bill: The Ozempic Cost Crisis Employers Can't Escape

> **Quick answer:** GLP-1 drugs like Ozempic, Wegovy, and Mounjaro are adding an estimated $275 per employee annually to employer health insurance costs in 2026 — spread across all workers, not just those using the medications. The math: at $766 per patient per month (net of rebates) with typical utilization rates, GLP-1 costs are absorbed across the entire covered workforce. Fifty-one percent of employers now call GLP-1s their top prescription drug cost driver, surpassing cancer medications. And nearly one in three employees says they would switch jobs to gain GLP-1 coverage — making this a retention crisis as much as a cost crisis.

*This article is for informational purposes only and does not constitute financial, medical, or insurance advice. Consult a qualified financial advisor or licensed insurance broker for decisions about your personal health coverage.*

GLP-1 drugs employer health insurance cost in 2026 has become the defining HR and benefits story of the year. Whether you take Ozempic or have never heard of semaglutide, if you get health insurance through your employer, you are almost certainly paying more because of these medications — and your employer is navigating a decision with no good options.

## The $275-Per-Employee Math: How GLP-1 Costs Spread Across Everyone

The headline figure — approximately $275 added to per-employee annual insurance costs — comes from how employer health plans actually work. When one drug category surges, the cost is not isolated to users. It spreads across the entire risk pool.